Blog
Early Detection of Cancer Annual Conference- EDx24 – hosted by Canary Center at Stanford, Cancer Research UK, & OHSU Knight Cancer Institute, and bringing together great minds to collaborate in cancer early detection research!November 1, 2024
The conference evolved from the formed international collaboration to accelerate research in the early detection of cancer including:
The goal of this unique trans-Atlantic agreement is to find lethal cancers as they are forming so they can be treated more effectively. Survival increases significantly when the disease is treated at an early stage. The collaboration also seeks to accelerate progress by breaking down barriers for scientists, including:
2024 session topics include:
Click here for the full agenda of speakers and topics: https://www.earlydetectionresearch.com/agenda/
|
Don Listwin Award For Outstanding Contribution to Cancer Early Detection 2024 goes to: Professor Antonis Antoniou
Prof Antonis Antoniou, Professor of Cancer Risk Prediction in the Department of Public Health and Primary Care, has been named as the 2024 of winner of the Don Listwin award for outstanding contribution to early cancer detection. Announced last night (23rd October) at the Early Detection of Cancer Conference in San Francisco, the award recognises a sustained contribution to, or singular achievement in, the cancer early detection field. The award is named in honour of Don Listwin, founder and chairman of the Canary Foundation, dedicated to research into early cancer detection. Antonis and team have been recognised for their work on developing risk prediction models for cancer, in particular for breast and ovarian cancers. These models can help doctors to predict who might be most at risk of certain cancers so that preventive and screening measures can be better targeted. The team’s CanRisk tool is used in primary care to calculate an individual’s future risks of developing breast and ovarian cancers using cancer family history, genetic and other risk factors. Since 2020 over 3 million assessments have been performed using CanRisk. Antonis said: I am deeply honoured that our work has been selected for the 2024 Don Listwin Award. This award reflects the remarkable dedication and contributions of our team, collaborators, healthcare professionals, patient and public partners, and everyone involved in the multidisciplinary work that underpins CanRisk. Over the years, this work has included developing novel statistical methods for modelling cancer susceptibility, understanding cancer risks for genetically susceptible individuals through large-scale collaborative studies, developing and validating multifactorial risk models, and transforming this research into user-friendly tools for clinicians. This has truly been a team effort. (credit @ Catherine Atkins from https://www.earlycancer.cam.ac.uk/news/prof-antonis-antoniou-announced-2024-don-listwin-award-winner#:~:text=We%20are%20thrilled%20to%20report,contribution%20to%20early%20cancer%20detection.) |
Canary Ovary Team is approaching a milestone of completing its first study of fallopian tubes.November 1, 2023 The Canary Ovary Team’s initiative to tackle High Grade Serous Ovarian Cancer (HGSOC) is approaching a milestone of completing its first study of fallopian tubes from women with and without mutations in the BRCA genes. HGSOC arises from the fallopian tubes, is the most common and deadly type of ovarian cancer, and women with BRCA mutations are at higher risk. The team has been carefully studying tubes to find whether there are BRCA-associated signals present at the molecular level, even in BRCA mutant tubes that appear “normal” under the microscope. When complete, this study will be the largest of its kind and will serve as a definitive resource for follow-up studies and for the research community focused on detecting ovarian cancer early. |
Don Listwin Award For Outstanding Contribution to Cancer Early Detection 2023 goes to: Professor Peter Sasieni
Congratulations to Professor Peter Sasieni, Academic Director of the Kings Clinical Trials Unit at King’s College London, who was presented with the 2023 Don Listwin award last night at the Early Detection of Cancer conference dinner. The award recognizes outstanding contribution to cancer early detection. Peter’s long career in cervical cancer prevention started with his first post-doctoral position at the Imperial Cancer Research Fund, looking at ways to optimize cervical cancer screening. He then looked at the potential for HPV testing to improve cervical cancer screening, followed by researching HPV vaccination as a means of cervical cancer prevention. The first HPV vaccinations were administered in 2006, and Peter was the lead author of the 2021 paper* showing that the implementation of HPV vaccination has led to a dramatic reduction in cervical cancer incidence. Peter has also been working with Professor Rebecca Fitzgerald on the BEST trials which have assessed the use of the Cytosponge “sponge on a string” device as a means of early detection and prevention of oesophageal cancer and are now exploring its implementation as a screening test for people on long-term medication for heart-burn symptoms, a risk factor for Barrett’s oesophagus, a potential precursor to oesophageal cancer. Peter’s award is richly deserved and we offer him our warmest congratulations. *Falcaro, Milena, Alejandra Castañon, Busani Ndlela, Marta Checchi, Kate Soldan, Jamie Lopez-Bernal, Lucy Elliss-Brookes, and Peter Sasieni. “The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.” The Lancet 398, no. 10316 (2021): 2084-2092. (credit @ Hannah Chang from https://www.earlycancer.cam.ac.uk/news/peter-sasieni-wins-2023-don-listwin-award) |
Early Detection of Cancer Annual Conference- EDx23 – hosted by Cancer Research UK, Canary Center at Stanford, & OHSU Knight Cancer Institute, and bringing together great minds to collaborate in cancer early detection research!
The Early Detection of Cancer Conference brought nearly 500 researchers, physicians, patients, industry leaders and supporters to London in October to share the latest findings in early detection of cancer. The conference was the largest since its inception and included lively debates, discussions, and presentations of recent advances including:
Click here for the full agenda of speakers and topics: |
Early Detection of Cancer Annual Conference- EDx22 – hosted by OHSU Knight Cancer Institute, The Canary Center at Stanford, and Cancer Research UK brought together great minds to collaborate in cancer early detection research!November 17, 2022 This year’s sold-out conference had engaging discussions, talks from submitted abstracts, and opportunities to collaborate with experts from across the globe. There was also the opportunity to debate provocative early detection challenges. This year’s interesting Agenda and Speakers: Keynote: Population and tumor heterogeneity in cancer genome science From models to mechanisms to humans Yeuk Pin Gladys Poon – The clonal evolution preceding leukemia development revealed using single-cell DNA sequencing Shiqin Liu – Shed Trop2 Extracellular Domain is a Potential Liquid Biomarker for High-risk Prostate Cancer and a Regulator of Prostate Cancer Progression Panel: How should we evaluate Multi Cancer Early Detection Tests? Emerging technologies for early detection and precision diagnosis Jie Wang – Acoustic Fabrication of Living Cardiomyocyte-based Hybrid Biorobots Travis Moore – Robust CNV detection using single-cell ATAC-seq Great Debate 1: There is no such thing as over-diagnosis. Every diagnosis will help us better understand the biology of the cancer, eventually advancing early cancer detection and management.
Day 2, Opening remarks – Tanya Stoyanova, Canary Center at Stanford University Keynote Panel: A funding agency perspective on early detection Microbiological risk factors for early detection Danielle Brasino – A New, Organ-on-Chip Platform to Study the Relationship Between Gut Microbiota and Distal Tumors Michael Fadel – Diagnostic performance of a non-invasive breath test for colorectal cancer: COlorectal BReath Analysis 1 (COBRA1) study Panel: What can we learn from trials that return unexpected results on mortality benefit from early detection biomarkers/tests? Great Debate 2: Single-organ cancer screening is failing public health – Multi-cancer early detection tests are the only way forward Day 3, Opening remarks – George Hanna, Imperial College London Joshua Bull – Mathematical Tools for Spatial Analysis of Multiplex Medical Images Elinor Nemlander – Predicting lung cancer in never smokers, former smokers and current smokers using machine learning – results from a computer-based detailed symptom questionnaire given to patients investigated at a specialist lung clinic What is needed for an earlier cancer detection test to have clinical impact? Conference closing remarks – George Hanna |
Don Listwin Award For Outstanding Contribution to Cancer Early Detection 2022 goes to: Sudhir Srivastava, Ph.D., MPH, MSNovember 16, 2022 The Don Listwin Award for Outstanding Contribution to Cancer Early Detection recognizes a sustained contribution to, or singular achievement in, the cancer early detection field. The 2022 Award goes to: Sudhir Srivastava, Ph.D., MPH, MS: Senior Scientific Officer and Chief of the Cancer Biomarkers Research Branch in the Division of Cancer Prevention, National Cancer Institute (NCI), National Institutes of Health (NIH). He is well-known for having established a number of transformative programs on translational research on cancer screening, early detection, risk assessment and enabling technologies including artificial intelligence with a network of leading experts in medicine, science, computational biology that has advanced scientific discoveries and revolutionized diagnostics in cancer early detection. In 2000, Dr. Srivastava developed and implemented a novel approach to collaborative clinical research on cancer biomarkers through the establishment of the Early Detection Research Network, a flagship program at the NCI that has begun translating biomarkers into clinical tests (> 8 FDA approved and > 19 CLIA certified) for early detection. This network has been a pioneer in applying innovative technologies in the validation of cancer biomarkers as well as in the development of a national informatics infrastructure to support the research. He also developed a number of strategic programs that promotes the convergence of interdisciplinary approaches from physics, biology, chemistry, and engineering emphasizing seamless integration of these disciplines into innovations, team science and translation from the bench to the bedside. These include EDRN, the Alliance of Glycobiologists, the Liver Cancer Consortium, the Liquid Biology Consortium, the Pancreatic Cancer Early Detection Consortium, the Cancer Imaging and Biomarkers Program, and the PreCancer Atlas. His conceptualization and implementation of the EDRN informatics infrastructure, in collaboration with NASA’s Jet Propulsion Laboratory, has become a model for similar collaboration established at the NIH. He is respected as an early adapter of emerging technologies, in particular, artificial intelligence initiatives he launched in 1994, before the science became omnipresence in the life sciences and a vital approach in today’s world of enhancing human capabilities. He has successfully developed partnerships on shared interests with the National Institute of Standards and Technology, DOD’s Center for Prostate Disease Research, DOE’s Pacific Northwest National Laboratory, and the Jet Propulsion Laboratory. In addition, he has developed collaborations with international and non-profit foundations, such as Japan’s Agency for Medical Development and Research, Cancer Research-UK, the China Cancer Institute/Chinese Academy of Medical Sciences, and U.S. organization such as Pancreatic Cancer Action Network, Lustgarten Foundation, and Kenner’s Family Research Foundation. In recognition of his leadership in cancer diagnostics, Dr. Srivastava was featured in Wired magazine in August 2003, and more recently, has been awarded a Distinguished Public Service Award (2016) by the American Pancreatology Association, a Distinguished Clinical and Translational Proteomics Award (2017) by HUPO International, and the Distinguished NCI Cancer Prevention Fellowship Program (CPFP) Alumni Award (2016). * Excerpt taken from https://www.earlydetectionresearch.com/award/ |
Early Detection of Cancer Annual Conference- EDx21 – hosted by Cancer Research UK, OHSU Knight Cancer Institute and the Canary Center at Stanford brought together the brightest minds in cancer early detection research!!November 29, 2021
|
Canary Scientists are on the right track!October 14, 2021 Canary Center continues as a world class facility, acting as a hub for innovative research, collaborations, cross-disciplined studies, and international partnerships. After their train ride, our scientists gave an informative update at a recent meeting observing distancing measures. Subjects covered included the Canary Center at Stanford, Ovarian and Prostate Programs and examples of work from the lab of Dr. Joseph DeSimone, who has been appointed as the inaugural Sanjiv Sam Gambhir Professor in Translational Medicine. Below are two highlights and a link to a 2-page report. Canary Ovarian Initiative is focusing on the microenvironment of the fallopian tubes, high grade serous carcinoma originates in the fallopian tubes, to look for changes that signal cancer.
Prostate Cancer Team and the Prostate Active Surveillance Study (PASS), more than a decade on, helps patients in the study as well as informing the medical profession on ways to understand which men are at greatest risk, requiring aggressive treatment versus those who have slow growing cancer. Recent Pass accomplishments include:
Read the full update report here: |
Don Listwin Award For Outstanding Contribution to Cancer Early Detection 2021 goes to Rebecca Fitzgerald, MD, FMedSciOctober 11, 2021 The Don Listwin Award for Outstanding Contribution to Cancer Early Detection recognizes a sustained contribution to, or singular achievement in, the cancer early detection field. The 2021 Award goes to: Rebecca Fitzgerald MD FMedSci, MRC Cancer Unit, University of Cambridge and an internationally recognized pioneer for her exceptional research into the prevention and detection of oesophageal cancers. This award was announced at the recent Early Detection of Cancer Conference – EDx21. This award is given to recognize and thank Rebecca for the work she has done to develop, grow and establish the research needed to detect cancer early. She is the Interim Director of the MRC Cancer Unit, Hutchison-MRC Research Centre, Professor of Cancer Prevention, and Clinician Scientist leading research in the Early Detection of Cancer for the University of Cambridge and the CRUK Alliance for Cancer Early Detection (ACED). Rebecca is known for the development of the Cytosponge technology, a sponge on a string that patients can swallow instead of undergoing an endoscopy. The Cytosponge collects cells from the oesophagus for staining, which can flag the presence of TFF3-positive cells indicative of Barrett’s oesophagus, a precursor to oesophageal cancer. Recently Rebecca and her team published work demonstrating that Cytosponge increases the identification of Barrett’s in individuals with frequent heart-burn symptoms by 10-fold compared to standard of care. The building of evidence for its clinical implementation for surveillance of high-risk individuals and in endoscopy sparing due to COVID-19 related pressures on health systems continues to make a vital impact to patients’ lives and is internationally recognized for its contribution towards breaking barriers in research. Congratulations to Rebecca and we are pleased to have her within the early detection community. |
« Older Entries |